Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands
Cosmos Health Inc. (NASDAQ:COSM) has reported a significant 160% increase in sales of its proprietary brands on Amazon UK for the year-to-date 2024. Sales have risen to $596,000 from $230,000 during the same period in 2023. The company's CEO, Greg Siokas, expressed satisfaction with the strong reception of their brands in the UK market and anticipates continued growth momentum. He also highlighted that the company's brands benefit from strong profit margins, which is expected to contribute to solid profitability as they expand their revenue base.
Cosmos Health Inc. (NASDAQ:COSM) ha riportato un aumento significativo del 160% nelle vendite dei suoi marchi proprietari su Amazon UK per l'anno fino ad oggi del 2024. Le vendite sono passate a $596.000 rispetto ai $230.000 dello stesso periodo del 2023. Il CEO dell'azienda, Greg Siokas, ha espresso soddisfazione per il forte ricevimento dei loro marchi nel mercato britannico e prevede un continuo slancio di crescita. Ha anche sottolineato che i marchi dell'azienda beneficiano di margini di profitto elevati, il che dovrebbe contribuire a una solidità della redditività mentre espandono la loro base di entrate.
Cosmos Health Inc. (NASDAQ:COSM) ha informado un incremento significativo del 160% en las ventas de sus marcas propias en Amazon UK en lo que va del año 2024. Las ventas han aumentado a $596,000 desde $230,000 durante el mismo período en 2023. El CEO de la compañía, Greg Siokas, expresó satisfacción por la fuerte acogida de sus marcas en el mercado británico y anticipa un continuo impulso de crecimiento. También destacó que las marcas de la empresa se benefician de márgenes de ganancia sólidos, lo que se espera que contribuya a una rentabilidad sólida a medida que amplían su base de ingresos.
코스모스 헬스 주식회사(Cosmos Health Inc., NASDAQ:COSM)는 2024년 현재까지 Amazon UK에서 자사 브랜드의 160% 판매 증가를 보고했습니다. 매출은 2023년 같은 기간의 $230,000에서 $596,000로 올랐습니다. 회사의 CEO인 Greg Siokas는 영국 시장에서 자사 브랜드의 강한 반응에 만족을 표하며 지속적인 성장 모멘텀을 예상했습니다. 그는 또한 회사 브랜드가 높은 이익률의 혜택을 보고 있으며, 이는 매출 기반 확장에 따라 안정적인 수익성에 기여할 것이라고 강조했습니다.
Cosmos Health Inc. (NASDAQ:COSM) a signalé une augmentation significative de 160% des ventes de ses marques propres sur Amazon UK pour l'année en cours 2024. Les ventes sont passées de $230,000 à $596,000 pendant la même période en 2023. Le PDG de l'entreprise, Greg Siokas, a exprimé sa satisfaction quant à la forte réception de leurs marques sur le marché britannique et anticipe une poursuite de la dynamique de croissance. Il a également souligné que les marques de l'entreprise bénéficient de marges bénéficiaires élevées, ce qui devrait contribuer à une rentabilité solide à mesure qu'elles élargissent leur base de revenus.
Cosmos Health Inc. (NASDAQ:COSM) hat einen signifikanten Anstieg von 160% im Verkauf seiner eigenen Marken auf Amazon UK für das Jahr bis heute 2024 gemeldet. Die Verkäufe sind von $230.000 im gleichen Zeitraum 2023 auf $596.000 gestiegen. Der CEO des Unternehmens, Greg Siokas, äußerte Zufriedenheit über die starke Resonanz ihrer Marken auf dem britischen Markt und erwartet ein anhaltendes Wachstum. Er hob auch hervor, dass die Marken des Unternehmens von starken Gewinnmargen profitieren, was voraussichtlich zur soliden Rentabilität beitragen wird, während sie ihre Einnahmebasis erweitern.
- 160% year-over-year increase in sales on Amazon UK
- Sales growth from $230,000 to $596,000 year-to-date
- Strong profit margins on proprietary brands
- None.
Insights
The 160% year-over-year increase in sales for Cosmos Health's proprietary brands on Amazon UK is a significant positive indicator for the company's growth trajectory. With sales jumping from
The emphasis on strong margins for these proprietary brands is particularly noteworthy. As sales volume increases, the potential for improved profitability becomes more pronounced, which could positively impact the company's bottom line. This growth in a key market like the UK also suggests potential for expansion into other regions, possibly leveraging Amazon's global platform.
However, investors should consider that while the percentage increase is impressive, the absolute dollar amount is still relatively small in the context of the overall healthcare market. The challenge for Cosmos Health will be to maintain this growth rate as the base number increases and to translate this e-commerce success into broader market penetration.
CHICAGO, IL / ACCESSWIRE / September 25, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that sales of its proprietary brands, including Sky Premium Life, on Amazon in the United Kingdom have surged by
Greg Siokas, CEO of Cosmos Health, stated: "We are delighted that our proprietary brands are being very well received by UK consumers, achieving impressive growth. We expect this strong momentum to continue. Importantly, our brands benefit from strong margins, positioning us for solid profitability as we continue to expand our revenue base."
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
SOURCE: Cosmos Health Inc.
View the original press release on accesswire.com
FAQ
What is the percentage increase in Cosmos Health's (COSM) Amazon UK sales for 2024?
How much are Cosmos Health's (COSM) year-to-date sales on Amazon UK in 2024?
Which brands are contributing to Cosmos Health's (COSM) sales growth on Amazon UK?
What does Cosmos Health's (COSM) CEO say about the company's profit margins?
